UB Paderborn / Katalog / Suche / in CDI

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

The Lancet (British edition), 2000-03, Vol.355 (9209), p.1041-1047

2000

Link zum Volltext

Verfügbarkeit prüfen

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1413-1424

1999

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group

Annals of oncology, 1994-07, Vol.5 (6), p.527

1994

Link zum Volltext

Verfügbarkeit prüfen

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-08, Vol.17 (8), p.2341-2354

1999

Link zum Volltext

Verfügbarkeit prüfen

Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard

The oncologist (Dayton, Ohio), 2001-01, Vol.6 (1), p.81-91

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

Cancer chemotherapy and pharmacology, 1995-01, Vol.35 (3), p.246-248

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Journal of cancer research and clinical oncology, 2008-02, Vol.134 (2), p.125-135

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans

Journal of clinical oncology, 1992-07, Vol.10 (7), p.1183-1190

1992

Link zum Volltext

Verfügbarkeit prüfen

Activity of Intoplicine (RP60475), a New DNA Topoisomerase I and II Inhibitor, Against Human Tumor Colony-Forming Units In Vitro

JNCI : Journal of the National Cancer Institute, 1994-01, Vol.86 (1), p.30-33

1994

Link zum Volltext

Verfügbarkeit prüfen

Specificity of the phase I trial for cytotoxic drugs in oncology

Fundamental & clinical pharmacology, 1990-01, Vol.4 (S2), p.197s-204s

1990

Link zum Volltext

Verfügbarkeit prüfen

The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis

European journal of cancer (1990), 1999-09, Vol.35, p.S194-S194

1999

Link zum Volltext

Verfügbarkeit prüfen

Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)

European journal of cancer (1990), 1999-09, Vol.35, p.S68-S68

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors

Anti-cancer drugs, 1999-11, Vol.10 (10), p.889-894

1999

Link zum Volltext

Verfügbarkeit prüfen

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1413

1999

Link zum Volltext

Verfügbarkeit prüfen

348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)

European journal of cancer (1990), 1995-11, Vol.31, p.S75-S76

1995

Link zum Volltext

Verfügbarkeit prüfen

Activity of intoplicine (RTP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vivo

JNCI : Journal of the National Cancer Institute, 1994, Vol.86 (1), p.30-33

1994

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer

Annals of oncology, 1994-07, Vol.5 (6), p.527-532

1994

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer : a study of the EORTC early chinical trials group

Annals of oncology, 1994, Vol.5 (6), p.527-532

1994

Link zum Volltext

Verfügbarkeit prüfen

A phase I and pharmacokinetic study of RP 60475F administered as a one hour IV infusion every 3 weeks in solid tumors

European journal of cancer (1990), 1993, Vol.29, p.S120-S120

1993

Link zum Volltext

Verfügbarkeit prüfen

Preparation, Characterization and Electrochemical Behavior of Pd-Au Alloy Incorporated into Zeolites/Graphite Electrodes

Electroanalysis (New York, N.Y.), 2014-08, Vol.26 (8), p.1810-1815

2014

Link zum Volltext

Verfügbarkeit prüfen

New circumcision clamp

The American journal of surgery, 1945-01, Vol.68 (3), p.402-402

Al Akl, F.M.

1945

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans

Activity of Intoplicine (RP60475), a New DNA Topoisomerase I and II Inhibitor, Against Human Tumor Colony-Forming Units In Vitro

Specificity of the phase I trial for cytotoxic drugs in oncology

The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis

Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)

Activity of intoplicine (RTP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vivo

A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer : a study of the EORTC early chinical trials group

A phase I and pharmacokinetic study of RP 60475F administered as a one hour IV infusion every 3 weeks in solid tumors

Preparation, Characterization and Electrochemical Behavior of Pd-Au Alloy Incorporated into Zeolites/Graphite Electrodes

New circumcision clamp

Suchergebnisse filtern